Pathogen reduction technology (Mirasol<sup>®</sup>) treated single‐donor platelets resuspended in a mixture of autologous plasma and PAS

Janetzko, Karin; Hinz, Katharina; Marschner, Susanne; Goodrich, Raymond P.; Klüter, Harald

doi:10.1111/j.1423-0410.2009.01193.x

Cited by 37 publications

(39 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…164,165 Pathogen reduction technologies (e.g., psoralen-based UV treatment) can reduce contamination risks, but so far these have extended the PC shelf-life only marginally. [165][166][167][168] Several other platelet-derived products are currently under investigation, e.g., frozen (−80 C) platelets, cold-stored (4 C) platelets, lyophilized platelets, platelet-derived microparticles and infusible platelet membranes (IPM), and trehalose-stabilized platelets (Thrombosomes; Cell-Phire, Rockville, Maryland, USA), with a vision to extend shelf-life of platelet-based hemostatic products without compromising biofunctional properties. [169][170][171][172] PCs and natural platelet-derived products are usually obtained from pooled blood of multiple donors, and this presents significant risks of blood-borne infection that, in turn, necessitates rigorous serological testing and expensive leukoreduction techniques.…”

Section: Platelet Substitutes Synthetic Hemostats and Platelet-inspmentioning

confidence: 99%

Bio‐inspired nanomedicine strategies for artificial blood components

Gupta

2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Blood is a fluid connective tissue where living cells are suspended in non-cellular liquid matrix. The cellular components of blood render gas exchange (RBCs), immune surveillance (WBCs) and hemostatic responses (platelets), and the non-cellular components (salts, proteins etc.) provide nutrition to various tissues in the body. Dysfunction and deficiencies in these blood components can lead to significant tissue morbidity and mortality. Consequently, transfusion of whole blood or its components is a clinical mainstay in the management of trauma, surgery, myelosuppression and congenital blood disorders. However, donor-derived blood products suffer from issues of shortage in supply, need for type matching, high risks of pathogenic contamination, limited portability and shelf-life, and a variety of side-effects. While robust research is being directed to resolve these issues, a parallel clinical interest has developed towards bioengineering of synthetic blood substitutes that can provide blood’s functions while circumventing the above problems. Nanotechnology has provided exciting approaches to achieve this, using materials engineering strategies to create synthetic and semi-synthetic RBC substitutes for enabling oxygen transport, platelet substitutes for enabling hemostasis and WBC substitutes for enabling cell-specific immune response. Some of these approaches have further extended the application of blood cell-inspired synthetic and semi-synthetic constructs for targeted drug delivery and nanomedicine. The current article will provide a comprehensive review of the various nanotechnology approaches to design synthetic blood cells, along with a critical discussion of successes and challenges of the current state-of-art in this field.

show abstract

Section: Platelet Substitutes Synthetic Hemostats and Platelet-inspmentioning

confidence: 99%

Bio‐inspired nanomedicine strategies for artificial blood components

Gupta

2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Although the introduction of PRT may negate the need for platelet irradiation, bacterial testing and additional donor screening tests, several aspects of in vitro platelet quality or function appear to be affected. A number of studies have concluded that the M‐PRT system exacerbates the effects of the platelet storage lesion [3–7]. However, in most cases, although significant, the in vitro changes to these platelet parameters are within the normal limits of acceptability.…”

Section: Introductionmentioning

confidence: 99%

The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…A number of studies have concluded that Mirasol treatment exacerbates the effects of the platelet storage lesion, resulting in increased glucose consumption, lactate production, and increased markers of platelet activation [2,3,4,5,6]. Further, we and others have previously demonstrated that Mirasol treatment affects platelet signal transduction and apoptotic protein expression [7,8,9,10].…”

Section: Introductionmentioning

confidence: 99%

Treatment of Platelet Concentrates with the Mirasol Pathogen Inactivation System Modulates Platelet Oxidative Stress and NF-κB Activation

Johnson¹,

Marks²

2015

Transfus Med Hemother

View full text Add to dashboard Cite

Background: Pathogen inactivation (PI) technologies for platelets aim to improve transfusion safety by preventing the replication of contaminating pathogens. However, as a consequence of treatment, aspects of the platelet storage lesion are amplified. Mirasol treatment also affects platelet signal transduction and apoptotic protein expression. The aim of this study was to examine the effect of Mirasol treatment on the generation of reactive oxygen species (ROS) and subsequent oxidative stress. Methods: Pooled platelet concentrates were prepared in platelet-additive solution (70% SSP+ / 30% plasma). ABO-matched platelets were pooled and split, and treated with the Mirasol system (TerumoBCT) or left untreated as a control. Platelet samples were tested on day 1, 5, and 7 post-collection. Results: Mirasol-treated platelets had increased formation of ROS by day 5 of storage. Oxidative damage, in the form of protein carbonylation, was higher in Mirasol-treated platelets, whilst no effect on nitrotyrosine formation or lipid peroxidation was detected. The NF-κB signaling pathway was also activated in Mirasol-treated platelets, with increased expression and phosphorylation of NF-κB p65 and IκBa. Conclusion: These data demonstrate that Mirasol-treated platelets produce more ROS and display protein alterations consistent with oxidative damage.

show abstract

Pathogen reduction technology (Mirasol^®) treated single‐donor platelets resuspended in a mixture of autologous plasma and PAS

Abstract: In comparison to PRT platelets resuspended in 100% plasma, a mixture of plasma and PAS improves pH and platelet metabolism but not platelet activation. Prolonged shelf-life for up to 7 days may be possible

Cited by 37 publications

References 26 publications

Bio‐inspired nanomedicine strategies for artificial blood components

Bio‐inspired nanomedicine strategies for artificial blood components

The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover

Treatment of Platelet Concentrates with the Mirasol Pathogen Inactivation System Modulates Platelet Oxidative Stress and NF-κB Activation

Contact Info

Product

Resources

About

Pathogen reduction technology (Mirasol®) treated single‐donor platelets resuspended in a mixture of autologous plasma and PAS

Abstract: In comparison to PRT platelets resuspended in 100% plasma, a mixture of plasma and PAS improves pH and platelet metabolism but not platelet activation. Prolonged shelf-life for up to 7 days may be possible

Cited by 37 publications

References 26 publications

Bio‐inspired nanomedicine strategies for artificial blood components

Bio‐inspired nanomedicine strategies for artificial blood components

The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover

Treatment of Platelet Concentrates with the Mirasol Pathogen Inactivation System Modulates Platelet Oxidative Stress and NF-&#954;B Activation

Contact Info

Product

Resources

About

Pathogen reduction technology (Mirasol^®) treated single‐donor platelets resuspended in a mixture of autologous plasma and PAS

Treatment of Platelet Concentrates with the Mirasol Pathogen Inactivation System Modulates Platelet Oxidative Stress and NF-κB Activation